COVID-19 vaccine candidates: A review

[1] Amanat F., Stadlbauer D., Strohmeier S., Nguyen T.H., Chromikova V., McMahon M., Jiang K., Arunkumar G.A., Jurczyszak D., Polanco J., Bermudez-Gonzalez M., Kleiner G., Aydillo T., Miorin L., Fierer D., et al.: A serological assay to detect SARS-CoV-2 serocon-version in humans. Nat. Med., 2020; 26: 1033–1036 AmanatF. StadlbauerD. StrohmeierS. NguyenT.H. ChromikovaV. McMahonM. JiangK. ArunkumarG.A. JurczyszakD. PolancoJ. Bermudez-GonzalezM. KleinerG. AydilloT. MiorinL. FiererD. A serological assay to detect SARS-CoV-2 serocon-version in humans Nat. Med. 2020 26 1033 1036 10.1038/s41591-020-0913-5 Search in Google Scholar

[2] AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19. https://www.astrazeneca.com/media-centre/press-releases/2020/azd1222hlr.html (13.01.2021) AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19 https://www.astrazeneca.com/media-centre/press-releases/2020/azd1222hlr.html (13.01.2021) Search in Google Scholar

[3] Baharoon S., Memish Z.A.: MERS-CoV as an emerging respiratory illness: A review of prevention methods. Travel. Med. Infect. Dis., 2019; 32: 101520 BaharoonS. MemishZ.A. MERS-CoV as an emerging respiratory illness: A review of prevention methods Travel. Med. Infect. Dis. 2019 32 101520 10.1016/j.tmaid.2019.101520 Search in Google Scholar

[4] Booth C.M., Matukas L.M., Tomlinson G.A., Rachlis A.R., Rose D.B., Dwosh H.A., Walmsley S.L., Mazzulli T., Avendano M., Derkach P., Ephtimios I.E., Kitai I., Mederski B.D., Shadowitz S.B., Gold W.L., et al.: Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA, 2003; 289: 2801–2809 BoothC.M. MatukasL.M. TomlinsonG.A. RachlisA.R. RoseD.B. DwoshH.A. WalmsleyS.L. MazzulliT. AvendanoM. DerkachP. EphtimiosI.E. KitaiI. MederskiB.D. ShadowitzS.B. GoldW.L. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area JAMA 2003 289 2801 2809 10.1001/jama.289.21.JOC30885 Search in Google Scholar

[5] Calina D., Docea A.O., Petrakis D., Egorow A.M., Ishmukhametov A.A., Gabibov A.G., Shtilman M.I., Kostoff R., Carvalho F., Vinceti M., Spandidos D.A., Tsatsakis A.: Towards effective COVID-19 vaccines: Updates, perspectives and challenges (review). Int. J. Mol. Med., 2020; 46: 3–16 CalinaD. DoceaA.O. PetrakisD. EgorowA.M. IshmukhametovA.A. GabibovA.G. ShtilmanM.I. KostoffR. CarvalhoF. VincetiM. SpandidosD.A. TsatsakisA. Towards effective COVID-19 vaccines: Updates, perspectives and challenges (review) Int. J. Mol. Med. 2020 46 3 16 10.3892/ijmm.2020.4596 Search in Google Scholar

[6] Calina D., Sarkar C., Arsene A.L., Salehi B., Docea A.O., Mondal M., Islam M.T., Zali A., Sharifi-Rad J.: Recent advances, approaches and challenges in targeting pathways for potential COVID-19 vaccines development. Immunol. Res., 2020; 68: 315–324 CalinaD. SarkarC. ArseneA.L. SalehiB. DoceaA.O. MondalM. IslamM.T. ZaliA. Sharifi-RadJ. Recent advances, approaches and challenges in targeting pathways for potential COVID-19 vaccines development Immunol. Res. 2020 68 315 324 10.1007/s12026-020-09154-4 Search in Google Scholar

[7] Callow K.A., Parry H.F., Sergeant M., Tyrrell D.A.: The time course of the immune response to experimental coronavirus infection of man. Epidemiol. Infect., 1990; 105: 435–446 CallowK.A. ParryH.F. SergeantM. TyrrellD.A. The time course of the immune response to experimental coronavirus infection of man Epidemiol. Infect. 1990 105 435 446 10.1017/S0950268800048019 Search in Google Scholar

[8] Cao W.C., Liu W., Zhang P.H., Zhang F., Richardus J.H.: Disappearance of antibodies to SARS-associated coronavirus after recovery. N. Engl. J. Med., 2007; 357: 1162–1163 CaoW.C. LiuW. ZhangP.H. ZhangF. RichardusJ.H. Disappearance of antibodies to SARS-associated coronavirus after recovery N. Engl. J. Med. 2007 357 1162 1163 10.1056/NEJMc070348 Search in Google Scholar

[9] ClinicalTrials.gov. https://clinicaltrials.gov/ct2/results?cond=Covid19&term=vaccine&cntry=&state=&city=&dist= (15.10.2020) ClinicalTrials.gov https://clinicaltrials.gov/ct2/results?cond=Covid19&term=vaccine&cntry=&state=&city=&dist= (15.10.2020) Search in Google Scholar

[10] Corey L., Mascola J.R., Fauci A.S., Collins F.S.: A strategic approach to COVID-19 vaccine R&D. Science, 2020; 368: 948–950 CoreyL. MascolaJ.R. FauciA.S. CollinsF.S. A strategic approach to COVID-19 vaccine R&D Science 2020 368 948 950 10.1126/science.abc5312 Search in Google Scholar

[11] Coronavirus. https://www.cdc.gov/coronavirus/types.html (15.10.2020) Coronavirus https://www.cdc.gov/coronavirus/types.html (15.10.2020) Search in Google Scholar

[12] DNA vaccines. https://www.who.int/teams/health-product-and-policy-standards/standards-and-specifications/vaccines-quality/dna (10.11.2020) DNA vaccines https://www.who.int/teams/health-product-and-policy-standards/standards-and-specifications/vaccines-quality/dna (10.11.2020) Search in Google Scholar

[13] Draft landscape of COVID-19 candidate vaccines. WHO. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines (15.10.2020) Draft landscape of COVID-19 candidate vaccines WHO https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines (15.10.2020) Search in Google Scholar

[14] Du Toit A.: Outbreak of a novel coronavirus. Nat. Rev. Microbiol., 2020; 18: 123 Du ToitA. Outbreak of a novel coronavirus Nat. Rev. Microbiol. 2020 18 123 10.1038/s41579-020-0332-0 Search in Google Scholar

[15] EMA recommends COVID-19 vaccine Moderna for authorisation in the EU. https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-moderna-authorisation-eu (13.01.2021) EMA recommends COVID-19 vaccine Moderna for authorisation in the EU https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-moderna-authorisation-eu (13.01.2021) Search in Google Scholar

[16] Explaining operation warp speed. https://www.hhs.gov/coronavirus/explaining-operation-warp-speed/index.html (13.01.2021) Explaining operation warp speed https://www.hhs.gov/coronavirus/explaining-operation-warp-speed/index.html (13.01.2021) Search in Google Scholar

[17] Folegatti P.M., Ewer K.J., Aley P.K., Angus B., Becker S., Belij-Rammerstorfer S., Bellamy D., Bibi S., Bittaye M., Clutterbuck E.A., Dold C., Faust S.N., Finn A., Flaxman A.L., Hallis B., et al.: Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet, 2020; 396: 467–478 FolegattiP.M. EwerK.J. AleyP.K. AngusB. BeckerS. Belij-RammerstorferS. BellamyD. BibiS. BittayeM. ClutterbuckE.A. DoldC. FaustS.N. FinnA. FlaxmanA.L. HallisB. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial Lancet 2020 396 467 478 10.1016/S0140-6736(20)31604-4 Search in Google Scholar

[18] Ge H., Wang X., Yuan X., Xiao G., Wang C., Deng T., Yuan Q., Xiao X.: The epidemiology and clinical information about COVID-19. Eur. J. Clin. Microbiol. Infect. Dis., 2020; 39: 1011–1019 GeH. WangX. YuanX. XiaoG. WangC. DengT. YuanQ. XiaoX. The epidemiology and clinical information about COVID-19 Eur. J. Clin. Microbiol. Infect. Dis. 2020 39 1011 1019 10.1007/s10096-020-03874-z Search in Google Scholar

[19] Graham B.S.: Rapid COVID-19 vaccine development. Science, 2020; 368: 945–946 GrahamB.S. Rapid COVID-19 vaccine development Science 2020 368 945 946 10.1126/science.abb8923 Search in Google Scholar

[20] Guarner J.: Three emerging coronaviruses in two decades. The story of SARS, MERS, and now COVID-19. Am. J. Clin. Pathol., 2020; 153: 420–421 GuarnerJ. Three emerging coronaviruses in two decades. The story of SARS, MERS, and now COVID-19 Am. J. Clin. Pathol. 2020 153 420 421 10.1093/ajcp/aqaa029 Search in Google Scholar

[21] Hasson S.S., Al-Busaidi J.K., Sallam T.A.: The past, current and future trends in DNA vaccine immunisations. Asian Pac. J. Trop. Biomed., 2015; 5: 344–353 HassonS.S. Al-BusaidiJ.K. SallamT.A. The past, current and future trends in DNA vaccine immunisations Asian Pac. J. Trop. Biomed. 2015 5 344 353 10.1016/S2221-1691(15)30366-X Search in Google Scholar

[22] Hsu L.Y., Lee C.C., Green J.A., Ang B., Paton N.I., Lee L., Villacian J.S., Lim P.L., Earnest A., Leo Y.S.: Severe acute respiratory syndrome (SARS) in Singapore: Clinical features of index patient and initial contacts. Emerg. Infect. Dis., 2003; 9: 713–717 HsuL.Y. LeeC.C. GreenJ.A. AngB. PatonN.I. LeeL. VillacianJ.S. LimP.L. EarnestA. LeoY.S. Severe acute respiratory syndrome (SARS) in Singapore: Clinical features of index patient and initial contacts Emerg. Infect. Dis. 2003 9 713 717 10.3201/eid0906.030264 Search in Google Scholar

[23] Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., Cheng Z., Yu T., Xia J., Wei Y., Wu W., et al.: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020; 395: 497–506 HuangC. WangY. LiX. RenL. ZhaoJ. HuY. ZhangL. FanG. XuJ. GuX. ChengZ. YuT. XiaJ. WeiY. WuW. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Lancet 2020 395 497 506 10.1016/S0140-6736(20)30183-5 Search in Google Scholar

[24] Huang L., Rong Y., Pan Q., Yi K., Tang X., Zhang Q., Wang W., Wu J., Wanga F.: SARS-CoV-2 vaccine research and development: conventional vaccines and biomimetic nanotechnology strategies. Asian J. Pharm. Sci., 2020; doi: 10.1016/j.ajps.2020.08.001 HuangL. RongY. PanQ. YiK. TangX. ZhangQ. WangW. WuJ. WangaF. SARS-CoV-2 vaccine research and development: conventional vaccines and biomimetic nanotechnology strategies Asian J. Pharm. Sci. 2020 10.1016/j.ajps.2020.08.001 746262932905011 Open DOISearch in Google Scholar

[25] Hui D.S., Zumla A.: Severe acute respiratory syndrome (SARS): Epidemiology and clinical features. Postgrad. Med. J., 2004; 80: 373–381 HuiD.S. ZumlaA. Severe acute respiratory syndrome (SARS): Epidemiology and clinical features Postgrad. Med. J. 2004 80 373 381 10.1136/pgmj.2004.020263174305415254300 Search in Google Scholar

[26] Interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States. https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html (13.01.2021) Interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html (13.01.2021) Search in Google Scholar

[27] Jackson L.A., Anderson E.J., Rouphael N.G., Roberts P.C., Makhene M., Coler R.N., McCullough M.P., Chappell J.D., Denison M.R., Stevens L.J., Pruijssers A.J., McDermott A., Flach B., Doria-Rose N.A., et al.: An mRNA vaccine against SARS-CoV-2 – preliminary report. N. Engl. J. Med., 2020; 383: 1920–1931 JacksonL.A. AndersonE.J. RouphaelN.G. RobertsP.C. MakheneM. ColerR.N. McCulloughM.P. ChappellJ.D. DenisonM.R. StevensL.J. PruijssersA.J. McDermottA. FlachB. Doria-RoseN.A. An mRNA vaccine against SARS-CoV-2 – preliminary report N. Engl. J. Med. 2020 383 1920 1931 10.1056/NEJMoa2022483737725832663912 Search in Google Scholar

[28] Jeyanathan M., Afkhami S., Smaill F., Miller M.S., Lichty B.D., Xing Z.: Immunological considerations for COVID-19 vaccine strategies. Nat. Rev. Immunol., 2020; 20: 615–632 JeyanathanM. AfkhamiS. SmaillF. MillerM.S. LichtyB.D. XingZ. Immunological considerations for COVID-19 vaccine strategies Nat. Rev. Immunol. 2020 20 615 632 10.1038/s41577-020-00434-6747268232887954 Search in Google Scholar

[29] Ki M.: 2015 MERS outbreak in Korea: Hospital-to-hospital transmission. Epidemiol. Health, 2015; 37: e2015033 KiM. 2015 MERS outbreak in Korea: Hospital-to-hospital transmission Epidemiol. Health 2015 37 e2015033 10.4178/epih/e2015033 Search in Google Scholar

[30] Lu R., Zhao X., Li J., Niu P., Yang B., Wu H., Wang W., Song H., Huang B., Zhu N., Bi Y., Ma X., Zhan F., Wang L., Hu T., et al.: Genomic characterization and epidemiology of 2019 novel corona-virus: Implications for virus origins and receptor binding. Lancet, 2020; 395: 565–574 LuR. ZhaoX. LiJ. NiuP. YangB. WuH. WangW. SongH. HuangB. ZhuN. BiY. MaX. ZhanF. WangL. HuT. Genomic characterization and epidemiology of 2019 novel corona-virus: Implications for virus origins and receptor binding Lancet 2020 395 565 574 10.1016/S0140-6736(20)30251-8 Search in Google Scholar

[31] Mao R., Qiu Y., He J.S., Tan J.Y., Li X.H., Liang J., Shen J., Zhu L.R., Chen Y., Iacucci M., Ng S.C., Ghosh S., Chen M.H.: Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: A systematic review and meta-analysis. Lancet Gastroenterol. Hepatol., 2020; 5: 667–678 MaoR. QiuY. HeJ.S. TanJ.Y. LiX.H. LiangJ. ShenJ. ZhuL.R. ChenY. IacucciM. NgS.C. GhoshS. ChenM.H. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: A systematic review and meta-analysis Lancet Gastroenterol. Hepatol. 2020 5 667 678 10.1016/S2468-1253(20)30126-6 Search in Google Scholar

[32] Masters P.S.: The molecular biology of coronaviruses. Adv. Virus Res., 2006; 66: 193–292 MastersP.S. The molecular biology of coronaviruses Adv. Virus Res. 2006 66 193 292 10.1016/S0065-3527(06)66005-3 Search in Google Scholar

[33] McBride R., van Zyl M., Fielding B.C.: The coronavirus nucleocapsid is a multifunctional protein. Viruses, 2014; 6: 2991–3018 McBrideR. van ZylM. FieldingB.C. The coronavirus nucleocapsid is a multifunctional protein Viruses 2014 6 2991 3018 10.3390/v6082991 Search in Google Scholar

[34] Middle East respiratory syndrome coronavirus (MERS-CoV). https://www.who.int/emergencies/mers-cov/en/ (15.10.2020) Middle East respiratory syndrome coronavirus (MERS-CoV) https://www.who.int/emergencies/mers-cov/en/ (15.10.2020) Search in Google Scholar

[35] Moderna COVID-19 vaccine. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccine (13.01.2021) Moderna COVID-19 vaccine https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccine (13.01.2021) Search in Google Scholar

[36] Mullard A.: COVID-19 vaccine development pipeline gears up. Lancet, 2020; 395: 1751–1752 MullardA. COVID-19 vaccine development pipeline gears up Lancet 2020 395 1751 1752 10.1016/S0140-6736(20)31252-6 Search in Google Scholar

[37] Mullol J., Alobid I., Mariño-Sánchez F., Izquierdo-Domínguez A., Marin C., Klimek L., Wang D.Y., Liu Z.: The loss of smell and taste in the COVID-19 outbreak: A tale of many countries. Curr. Allergy Asthma Rep., 2020; 20: 61 MullolJ. AlobidI. Mariño-SánchezF. Izquierdo-DomínguezA. MarinC. KlimekL. WangD.Y. LiuZ. The loss of smell and taste in the COVID-19 outbreak: A tale of many countries Curr. Allergy Asthma Rep. 2020 20 61 10.1007/s11882-020-00961-1739745332748211 Search in Google Scholar

[38] Neuman B.W., Kiss G., Kunding A.H., Bhella D., Baksh M.F., Connelly S., Droese B., Klaus J.P., Makino S., Sawicki S.G., Siddell S.G., Stamou D.G., Wilson I.A., Kuhn P., Buchmeier M.J.: A structural analysis of M protein in coronavirus assembly and morphology. J. Struct. Biol., 2011; 174: 11–22 NeumanB.W. KissG. KundingA.H. BhellaD. BakshM.F. ConnellyS. DroeseB. KlausJ.P. MakinoS. SawickiS.G. SiddellS.G. StamouD.G. WilsonI.A. KuhnP. BuchmeierM.J. A structural analysis of M protein in coronavirus assembly and morphology J. Struct. Biol. 2011 174 11 22 10.1016/j.jsb.2010.11.021448606121130884 Search in Google Scholar

[39] Padron-Regalado E.: Vaccines for SARS-CoV-2: Lessons from other coronavirus strains. Infect. Dis. Ther., 2020; 9: 255–274 Padron-RegaladoE. Vaccines for SARS-CoV-2: Lessons from other coronavirus strains Infect. Dis. Ther. 2020 9 255 274 10.1007/s40121-020-00300-x717704832328406 Search in Google Scholar

[40] Pardi N., Hogan M.J., Porter F.W., Weissman D.: mRNA vaccines – a new era in vaccinology. Nat. Rev. Drug Discov., 2018; 17: 261–279 PardiN. HoganM.J. PorterF.W. WeissmanD. mRNA vaccines – a new era in vaccinology Nat. Rev. Drug Discov. 2018 17 261 279 10.1038/nrd.2017.243590679929326426 Search in Google Scholar

[41] Peeples L.: News feature: Avoiding pitfalls in the pursuit of a COVID-19 vaccine. Proc. Natl. Acad. Sci. USA, 2020; 117: 8218–8221 PeeplesL. News feature: Avoiding pitfalls in the pursuit of a COVID-19 vaccine Proc. Natl. Acad. Sci. USA 2020 117 8218 8221 10.1073/pnas.2005456117716547032229574 Search in Google Scholar

[42] Peiris J.S.: Coronaviruses. In: Medical microbiology, ed.: D. Greenwood, M. Barer, R. Slack, W. Irving. Churchill Livingstone, Edinburgh 2012, 587–593 PeirisJ.S. Coronaviruses In: Medical microbiology ed.: GreenwoodD. BarerM. SlackR. IrvingW. Churchill Livingstone Edinburgh 2012 587 593 10.1016/B978-0-7020-4089-4.00072-X Search in Google Scholar

[43] Pfizer and BioNTech announce vaccine candidate against COVID-19 achieved success in first interim analysis from phase 3 study. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against (09.11.2020) Pfizer and BioNTech announce vaccine candidate against COVID-19 achieved success in first interim analysis from phase 3 study https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against (09.11.2020) Search in Google Scholar

[44] Project Lightspeed. https://biontech.de/covid-19-portal/project-lightspeed (13.01.2021) Project Lightspeed https://biontech.de/covid-19-portal/project-lightspeed (13.01.2021) Search in Google Scholar

[45] Romano M., Ruggiero A., Squeglia F., Maga G., Berisio R.: A structural view of SARS-CoV-2 RNA replication machinery: RNA synthesis, proofreading and final capping. Cells, 2020; 9: 1267 RomanoM. RuggieroA. SquegliaF. MagaG. BerisioR. A structural view of SARS-CoV-2 RNA replication machinery: RNA synthesis, proofreading and final capping Cells 2020 9 1267 10.3390/cells9051267729102632443810 Search in Google Scholar

[46] Ruch T.R., Machamer C.E.: The hydrophobic domain of infectious bronchitis virus E protein alters the host secretory pathway and is important for release of infectious virus. J. Virol., 2011; 85: 675–685 RuchT.R. MachamerC.E. The hydrophobic domain of infectious bronchitis virus E protein alters the host secretory pathway and is important for release of infectious virus J. Virol. 2011 85 675 685 10.1128/JVI.01570-10302003221047962 Search in Google Scholar

[47] SARS (Severe acute respiratory syndrome). https://www.who.int/ith/diseases/sars/en/ (15.10.2020) SARS (Severe acute respiratory syndrome) https://www.who.int/ith/diseases/sars/en/ (15.10.2020) Search in Google Scholar

[48] Satarker S., Nampoothiri M.: Structural proteins in severe acute respiratory syndrome coronavirus-2. Arch. Med. Res., 2020; 51: 482–491 SatarkerS. NampoothiriM. Structural proteins in severe acute respiratory syndrome coronavirus-2 Arch. Med. Res. 2020 51 482 491 10.1016/j.arcmed.2020.05.012724749932493627 Search in Google Scholar

[49] Schoeman D., Fielding B.C.: Coronavirus envelope protein: Current knowledge. Virol. J., 2019; 16: 69 SchoemanD. FieldingB.C. Coronavirus envelope protein: Current knowledge Virol. J. 2019 16 69 10.1186/s12985-019-1182-0653727931133031 Search in Google Scholar

[50] Sorbello M., El-Boghdadly K., Di Giacinto I., Cataldo R., Esposito C., Falcetta S., Merli G., Cortese G., Corso R.M., Bressan F., Pintaudi S., Greif R., Donati A., Petrini F.: The Italian coronavirus disease 2019 outbreak: Recommendations from clinical practice. Anaesthesia, 2020; 75: 724–732 SorbelloM. El-BoghdadlyK. Di GiacintoI. CataldoR. EspositoC. FalcettaS. MerliG. CorteseG. CorsoR.M. BressanF. PintaudiS. GreifR. DonatiA. PetriniF. The Italian coronavirus disease 2019 outbreak: Recommendations from clinical practice Anaesthesia 2020 75 724 732 10.1111/anae.1504932221973 Search in Google Scholar

[51] Sternberg A., Naujokat C.: Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination. Life Sci., 2020; 257: 118056 SternbergA. NaujokatC. Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination Life Sci. 2020 257 118056 10.1016/j.lfs.2020.118056733613032645344 Search in Google Scholar

[52] Su S., Wong G., Shi W., Liu J., Lai A.C., Zhou J., Liu W., Bi Y., Gao G.F.: Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol., 2016; 24: 490–502 SuS. WongG. ShiW. LiuJ. LaiA.C. ZhouJ. LiuW. BiY. GaoG.F. Epidemiology, genetic recombination, and pathogenesis of coronaviruses Trends Microbiol. 2016 24 490 502 10.1016/j.tim.2016.03.003712551127012512 Search in Google Scholar

[53] Tao Y., Shi M., Chommanard C., Queen K., Zhang J., Markotter W., Kuzmin I.V., Holmes E.C., Tong S.: Surveillance of bat coronaviruses in Kenya identifies relatives of human coronaviruses NL63 and 229E and their recombination history. J. Virol., 2017; 91: e01953–16 TaoY. ShiM. ChommanardC. QueenK. ZhangJ. MarkotterW. KuzminI.V. HolmesE.C. TongS. Surveillance of bat coronaviruses in Kenya identifies relatives of human coronaviruses NL63 and 229E and their recombination history J. Virol. 2017 91 e01953 16 10.1128/JVI.01953-16530995828077633 Search in Google Scholar

[54] Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J., Wang B., Xiang H., Cheng Z., Xiong Y., Zhao Y., Li Y., Wang X., Peng Z.: Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA, 2020; 323: 1061–1069 WangD. HuB. HuC. ZhuF. LiuX. ZhangJ. WangB. XiangH. ChengZ. XiongY. ZhaoY. LiY. WangX. PengZ. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China JAMA 2020 323 1061 1069 10.1001/jama.2020.1585704288132031570 Search in Google Scholar

[55] Zhou P., Yang X.L., Wang X.G., Hu B., Zhang L., Zhang W., Si H.R., Zhu Y., Li B., Huang C.L., Chen H.D., Chen J., Luo Y., Guo H., Jiang R.D., et al.: A pneumonia outbreak associated with a new corona-virus of probable bat origin. Nature, 2020; 579: 270–273 ZhouP. YangX.L. WangX.G. HuB. ZhangL. ZhangW. SiH.R. ZhuY. LiB. HuangC.L. ChenH.D. ChenJ. LuoY. GuoH. JiangR.D. A pneumonia outbreak associated with a new corona-virus of probable bat origin Nature 2020 579 270 273 10.1038/s41586-020-2012-7709541832015507 Search in Google Scholar